Technology | Antiplatelet and Anticoagulation Therapies | October 17, 2018

FDA Clears Rivaroxaban to Reduce the Risk of Major Cardiovascular Events

New indication is for patients with chronic coronary artery disease (CAD) or peripheral artery disease (PAD)

Rivaroxaban (Xeralto) is now cleared by the FDA with a new indication is for patients with chronic coronary artery disease (CAD) or peripheral artery disease (PAD).

October 17, 2018 — The U.S. Food and Drug Administration (FDA) has cleared an additional indication for rivaroxaban (Xarelto) to reduce the risk of major cardiovascular (CV) events, such as CV death, myocardial infarction (MI) and stroke, in people with chronic coronary or peripheral artery disease (CAD/PAD). The drug is now the first and only factor Xa inhibitor approved for patients living with these conditions. The drug is made by The Janssen Pharmaceutical Companies of Johnson and Johnson. 

This new indication is based on results from the landmark COMPASS Trial,[1] which showed a significant 24 percent reduction of the risk of major CV events in patients with chronic CAD and/or PAD with the rivaroxaban vascular dose of 2.5 mg twice daily plus aspirin 100 mg once daily, compared to aspirin alone. This finding was driven by a 42 percent reduction in stroke, 22 percent reduction in CV death and 14 percent reduction in heart attack. The risk of major bleeding was significantly higher in patients taking the rivaroxaban/aspirin regimen compared to aspirin alone, with no significant increase in fatal or intracranial bleeds.

“Treating patients with aspirin only is simply not enough to address the underlying thrombotic risk that comes with CAD and PAD,” said Kelley Branch, M.D., M.Sc., FACC, FSCCT, associate professor in cardiology, University of Washington, Seattle. “As we saw in the COMPASS Trial, the dual pathway approach of aspirin and the 2.5 mg, twice-daily dose of Xarelto can help significantly reduce the risk of CV events in these populations.”

Both chronic CAD and PAD occur when arteries become hardened or narrowed due to a buildup of cholesterol and plaque, potentially limiting blood flow to parts of the body. Known as atherosclerosis, this disease is rarely fatal, but is the most frequent underlying cause of CAD and PAD, which affect 16.5 million and 10 million Americans, 13 million of whom are currently diagnosed. When left untreated, atherosclerosis can lead to serious problems, including heart attack, stroke and death.[2,3]

“Despite the use of guideline-recommended therapies, patients with chronic CAD and/or PAD remain at risk of having a devastating and irreversible CV event,” said Paul Burton, M.D., Ph.D., FACC, vice president, medical affairs, internal medicine, Janssen Scientific Affairs LLC. “The new Xarelto vascular 2.5 mg dose, when used with aspirin, represents a true breakthrough for patients with chronic CAD and PAD.”

Details on the COMPASS Trial

COMPASS was a phase 3 clinical study of 27,395 patients with chronic CAD or PAD from 33 countries, examined the use of rivaroxaban, alone or in combination with aspirin, for the long-term prevention of major adverse CV events, including heart attack, stroke and CV death. In February 2017, COMPASS was stopped early for efficacy based on recommendation of the Independent Data and Safety Monitoring Board who observed a consistent difference in the primary outcome in favor of rivaroxaban 2.5 mg plus aspirin. The COMPASS results were presented during a Hot Line session at the ESC Congress 2017 and simultaneously published in The New England Journal of Medicine.[1] Two sub-analyses from COMPASS in patients with PAD and CAD were also published in The Lancet

COMPASS is a part of the industry-leading EXPLORER clinical development program, a collaborative effort between Janssen and Bayer, which seeks to generate important clinical evidence on the safety and efficacy of rivaroxaban and its potential role in addressing a wide range of critical medical needs. 

Read about the results of rivaroxaban in PAD from the late-breakers at ACC 2018. 

In July 2018, Janssen’s development partner Bayer announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) granted a positive opinion to update the rivaroxaban label to include the new vascular indication in the European Union; the European Commission granted approval on Aug. 24, 2018. Since its launch, rivaroxaban has been approved for a variety of indications and prescribed more than 45 million times worldwide.

 

References:

1. J.W. Eikelboom, S.J. Connolly, J. Bosch, et al. Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease. N Engl J Med. 2017;377:1319-30. DOI: 10.1056/NEJMoa1709118

2. Heart Disease and Stroke Statistics—2017 Update: A Report From the American Heart Association. Circulation. 2017; CIR.0000000000000485;ii AHA Statistical Update. Originally published Jan. 25, 2017, page 360.

3. AHA Statistical Update, Heart Disease and Stroke Statistics—2017 Update: A Report From the American Heart Association. Circulation. 2017;CIR.0000000000000485. Originally published Jan. 25, 2017, page 408. h

Related Content

Videos | Antiplatelet and Anticoagulation Therapies | October 11, 2019
Ajay J. Kirtane, M.D., associate professor of medicine at Columbia University Irving Medical Center and director of the...
Videos | Antiplatelet and Anticoagulation Therapies | October 08, 2019
American Heart Association President Robert Harrington, M.D., explains the reasons for shorter duration dual-...
Three-Month DAPT Post-PCI Demonstrates Low Adverse Event Rate in High-Bleeding Risk Patients
News | Antiplatelet and Anticoagulation Therapies | September 30, 2019
Data from the EVOLVE Short DAPT study found that shortened three-month dual antiplatelet therapy (DAPT) did not...
Brilinta Monotherapy Reduces Clinically Relevant Bleeding Risk Post-PCI in High-Risk Patients
News | Antiplatelet and Anticoagulation Therapies | September 26, 2019
New data from the Phase IV independent TWILIGHT trial showed Brilinta (ticagrelor) monotherapy reduced the risk of BARC...
Aspirin Should Not Be Recommended for Healthy People Over 70
News | Antiplatelet and Anticoagulation Therapies | September 20, 2019
Low-dose aspirin does not prolong disability-free survival of healthy people over 70, even in those at the highest risk...
Ticagrelor Plus Aspirin Reduces Ischemic Events in Stable Coronary Patients With Diabetes
News | Antiplatelet and Anticoagulation Therapies | September 10, 2019
The combination of ticagrelor and aspirin reduces ischemic events compared with aspirin alone in patients with stable...
Prasugrel Cuts Ischemic Events in Acute Coronary Syndrome Patients
News | Antiplatelet and Anticoagulation Therapies | September 09, 2019
Prasugrel is superior to ticagrelor for reducing ischemic events in patients with acute coronary syndrome and a planned...
Advances in Anticoagulants Expand Options for VTE Prevention, Treatment
News | Antiplatelet and Anticoagulation Therapies | July 26, 2019
A new article published in AACN Advanced Critical Care outlines the traditional anticoagulant therapies familiar to...
Overlay Init